Accession Therapeutics

Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform.

Designed for systemic delivery, the platform selectively replicates within cancer cells to generate therapeutic payloads locally at the tumour site.

The company’s lead programme is advancing toward Phase 1 clinical trials for advanced solid tumours.

The platform is intended to support multiple cancer indications and immuno-oncology approaches.